AVALON GLOBOC.NEW -,0001
AVALON GLOBOC.NEW -,0001
Share · US05344R2031 · ALBT · A3D4QG (XNCM)
Overview Financial Indicators
2,85 EUR
-4,40 % -0,13 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
09.06.2025 19:59

Current Prices from AVALON GLOBOC.NEW -,0001

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ALBT
USD
09.06.2025 19:59
3,26 USD
3,41 USD
-4,40 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-4,57 % -4,75 % -13,91 % -54,66 % -25,99 % -56,24 % -98,79 %

Company Profile for AVALON GLOBOC.NEW -,0001 Share

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Company Data

Name AVALON GLOBOC.NEW -,0001
Company Avalon GloboCare Corp.
Symbol ALBT
Website https://www.avalon-globocare.com
Primary Exchange XNCM Frankfurt
WKN A3D4QG
ISIN US05344R2031
Asset Class Share
Sector Real Estate
Industry Real Estate - Services
CEO Dr. David K. Jin M.D., Ph.D.
Country United States of America
Currency EUR
Employees 0,0 T
Address 4400 Route 9 South, 07728 Freehold
IPO Date 2018-03-27

Stock Splits

Date Split
28.10.2024 1:15

ID Changes

Date From To
10.11.2022 AVCO ALBT

Ticker Symbols

Name Symbol
NASDAQ ALBT

More Shares

Investors who AVALON GLOBOC.NEW -,0001 hold also have the following shares in their portfolio:
ENEL F. INTL 21/28 REGS
ENEL F. INTL 21/28 REGS Bond
HSBC BANK PLC BARR RVRSE CONV NTS FTSE 100 15/04/24
HSBC BANK PLC BARR RVRSE CONV NTS FTSE 100 15/04/24 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025